Annual Cash & Cash Equivalents
$58.53 M
+$359.00 K+0.62%
December 31, 2024
Summary
- As of February 26, 2025, TVTX annual cash & cash equivalents is $58.53 million, with the most recent change of +$359.00 thousand (+0.62%) on December 31, 2024.
- During the last 3 years, TVTX annual cash & cash equivalents has fallen by -$107.22 million (-64.69%).
- TVTX annual cash & cash equivalents is now -64.69% below its all-time high of $165.75 million, reached on December 31, 2021.
Performance
TVTX Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$58.53 M
+$22.13 M+60.77%
December 1, 2024
Summary
- As of February 26, 2025, TVTX quarterly cash and cash equivalents is $58.53 million, with the most recent change of +$22.13 million (+60.77%) on December 1, 2024.
- Over the past year, TVTX quarterly cash and cash equivalents has increased by +$359.00 thousand (+0.62%).
- TVTX quarterly cash and cash equivalents is now -77.19% below its all-time high of $256.57 million, reached on March 31, 2022.
Performance
TVTX Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
TVTX Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +0.6% | +0.6% |
| 3 y3 years | -64.7% | +0.6% |
| 5 y5 years | -6.3% | +0.6% |
TVTX Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -64.7% | +0.6% | -77.2% | +81.3% |
| 5 y | 5-year | -64.7% | +0.6% | -77.2% | +81.3% |
| alltime | all time | -64.7% | >+9999.0% | -77.2% | >+9999.0% |
Travere Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $58.53 M(+0.6%) | - |
| Dec 2024 | - | $58.53 M(+60.8%) |
| Sep 2024 | - | $36.41 M(+12.8%) |
| Jun 2024 | - | $32.29 M(-25.3%) |
| Mar 2024 | - | $43.25 M(-25.7%) |
| Dec 2023 | $58.18 M(-5.7%) | $58.18 M(-59.7%) |
| Sep 2023 | - | $144.24 M(+103.5%) |
| Jun 2023 | - | $70.87 M(-56.1%) |
| Mar 2023 | - | $161.38 M(+161.6%) |
| Dec 2022 | $61.69 M(-62.8%) | $61.69 M(-59.2%) |
| Sep 2022 | - | $151.34 M(-15.8%) |
| Jun 2022 | - | $179.76 M(-29.9%) |
| Mar 2022 | - | $256.57 M(+54.8%) |
| Dec 2021 | $165.75 M(+95.5%) | $165.75 M(+10.3%) |
| Sep 2021 | - | $150.33 M(+80.5%) |
| Jun 2021 | - | $83.29 M(-43.8%) |
| Mar 2021 | - | $148.23 M(+74.9%) |
| Dec 2020 | $84.77 M(+35.8%) | $84.77 M(-57.7%) |
| Sep 2020 | - | $200.48 M(-15.5%) |
| Jun 2020 | - | $237.17 M(+253.9%) |
| Mar 2020 | - | $67.02 M(+7.3%) |
| Dec 2019 | $62.44 M(-39.3%) | $62.44 M(-4.2%) |
| Sep 2019 | - | $65.19 M(-13.8%) |
| Jun 2019 | - | $75.66 M(+8.3%) |
| Mar 2019 | - | $69.84 M(-32.1%) |
| Dec 2018 | $102.87 M(+3.5%) | $102.87 M(-33.6%) |
| Sep 2018 | - | $154.82 M(+73.4%) |
| Jun 2018 | - | $89.31 M(+46.1%) |
| Mar 2018 | - | $61.12 M(-38.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2017 | $99.39 M(+142.4%) | $99.39 M(+0.4%) |
| Sep 2017 | - | $98.99 M(+10.9%) |
| Jun 2017 | - | $89.27 M(+113.2%) |
| Mar 2017 | - | $41.87 M(+2.1%) |
| Dec 2016 | $41.00 M(+8.5%) | $41.00 M(+71.6%) |
| Sep 2016 | - | $23.89 M(+13.0%) |
| Jun 2016 | - | $21.16 M(-9.1%) |
| Mar 2016 | - | $23.26 M(-38.5%) |
| Dec 2015 | $37.80 M(+107.7%) | $37.80 M(-73.1%) |
| Sep 2015 | - | $140.60 M(+10.1%) |
| Jun 2015 | - | $127.75 M(+6.3%) |
| Mar 2015 | - | $120.17 M(+560.2%) |
| Dec 2014 | $18.20 M(+203.5%) | $18.20 M(-29.6%) |
| Sep 2014 | - | $25.86 M(-35.2%) |
| Jun 2014 | - | $39.88 M(+979.2%) |
| Mar 2014 | - | $3.70 M(-38.4%) |
| Dec 2013 | $6.00 M(>+9900.0%) | $6.00 M(-55.3%) |
| Sep 2013 | - | $13.41 M(+4580.6%) |
| Jun 2013 | - | $286.50 K(-88.6%) |
| Mar 2013 | - | $2.50 M(>+9900.0%) |
| Dec 2012 | $11.40 K(+192.3%) | - |
| Nov 2012 | - | $3900.00(0.0%) |
| Aug 2012 | - | $3900.00(0.0%) |
| May 2012 | - | $3900.00(0.0%) |
| Feb 2012 | - | $3900.00(0.0%) |
| Feb 2012 | $3900.00(-2.5%) | - |
| Nov 2011 | - | $3900.00(0.0%) |
| Aug 2011 | - | $3900.00(-2.5%) |
| Feb 2011 | $4000.00 | $4000.00 |
FAQ
- What is Travere Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Travere Therapeutics?
- What is Travere Therapeutics annual cash & cash equivalents year-on-year change?
- What is Travere Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Travere Therapeutics?
- What is Travere Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Travere Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of TVTX is $58.53 M
What is the all time high annual cash & cash equivalents for Travere Therapeutics?
Travere Therapeutics all-time high annual cash & cash equivalents is $165.75 M
What is Travere Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, TVTX annual cash & cash equivalents has changed by +$359.00 K (+0.62%)
What is Travere Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of TVTX is $58.53 M
What is the all time high quarterly cash and cash equivalents for Travere Therapeutics?
Travere Therapeutics all-time high quarterly cash and cash equivalents is $256.57 M
What is Travere Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, TVTX quarterly cash and cash equivalents has changed by +$359.00 K (+0.62%)